140 related articles for article (PubMed ID: 35117577)
1. Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
Schulz C; Stintzing S
Transl Cancer Res; 2020 Apr; 9(4):2175-2177. PubMed ID: 35117577
[No Abstract] [Full Text] [Related]
2. Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?
Perkhofer L; Hann A
Transl Cancer Res; 2019 Sep; 8(5):1656-1658. PubMed ID: 35116913
[No Abstract] [Full Text] [Related]
3. Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas.
Li-Chang HH; Kasaian K; Ng Y; Lum A; Kong E; Lim H; Jones SJ; Huntsman DG; Schaeffer DF; Yip S
BMC Cancer; 2015 Feb; 15():32. PubMed ID: 25656989
[TBL] [Abstract][Full Text] [Related]
4. HER2 status in Gastric and Gastroesophageal Junction Adenocarcinoma.
Rima FA; Hussain M; Haque N; Dewan RK; Rahman N; Jinnah MA; Jeba R; Chowdhury F
Mymensingh Med J; 2017 Apr; 26(2):372-379. PubMed ID: 28588175
[TBL] [Abstract][Full Text] [Related]
5. High Interobserver Variability Among Pathologists Using Combined Positive Score to Evaluate PD-L1 Expression in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma.
Robert ME; Rüschoff J; Jasani B; Graham RP; Badve SS; Rodriguez-Justo M; Kodach LL; Srivastava A; Wang HL; Tang LH; Troncone G; Rojo F; Van Treeck BJ; Pratt J; Shnitsa I; Kumar G; Karasarides M; Anders RA
Mod Pathol; 2023 May; 36(5):100154. PubMed ID: 36925069
[TBL] [Abstract][Full Text] [Related]
6. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment.
Kunz PL; Mojtahed A; Fisher GA; Ford JM; Chang DT; Balise RR; Bangs CD; Cherry AM; Pai RK
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):13-24. PubMed ID: 21617522
[TBL] [Abstract][Full Text] [Related]
7. Near infrared ray-guided surgery using Firefly technology of the daVinci Xi system and intraoperative upper gastrointestinal endoscopy for subtotal gastrectomy and surgery for cancer of the gastroesophageal junction.
Sagawa H; Saito M; Ito S; Hayakawa S; Ueno S; Okubo T; Tanaka T; Ogawa R; Takahashi H; Matsuo Y; Mitsui A; Kimura M; Takiguchi S
BMC Surg; 2022 May; 22(1):174. PubMed ID: 35549907
[TBL] [Abstract][Full Text] [Related]
8. A Systematic Review and Meta-analysis of PD-1 and PD-L1 Inhibitors Monotherapy in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma.
Voutsadakis IA
Euroasian J Hepatogastroenterol; 2020; 10(2):56-63. PubMed ID: 33511066
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of PD-1 Inhibitors in First-Line Treatment for Advanced Gastroesophageal Junction and Gastric Cancer by Subgroups: A Systematic Review and Meta-Analysis.
Fei S; Lu Y; Chen J; Qi J; Wu W; Wang B; Han Y; Wang K; Han X; Zhou H; Wang J; Chen J
Chemotherapy; 2023; 68(4):197-209. PubMed ID: 37331333
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of HER2 Expression and Its Correlation with Clinicopathological Parameters in Gastric or Gastroesophageal Junction Adenocarcinoma in North-East Indian Population.
Roy PS; Nyodu T; Hazarika M; Saikia BJ; Bhuyan C; Inamdar A; Nyuthe CW; Borthakur B; Sharma JD
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1139-1145. PubMed ID: 31030487
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological Review of Gastroesophageal Junction Adenocarcinoma in Asian Countries.
Manabe N; Matsueda K; Haruma K
Digestion; 2022; 103(1):29-36. PubMed ID: 34718236
[TBL] [Abstract][Full Text] [Related]
12. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction.
Chen XF; Zhang B; Chen ZX; Hu JK; Dai B; Wang F; Yang HX; Chen JP
Dig Dis Sci; 2012 Mar; 57(3):738-45. PubMed ID: 21953142
[TBL] [Abstract][Full Text] [Related]
13. The prevalence of Helicobacter pylori infection and the status of gastric acid secretion in patients with gastroesophageal junction adenocarcinoma in Japan.
Koike T; Ohara S; Inomata Y; Abe Y; Iijima K; Shimosegawa T
Inflammopharmacology; 2007 Apr; 15(2):61-4. PubMed ID: 17450443
[TBL] [Abstract][Full Text] [Related]
14. Preservation of gastric acid secretion may be important for the development of gastroesophageal junction adenocarcinoma in Japanese people, irrespective of the H. pylori infection status.
Inomata Y; Koike T; Ohara S; Abe Y; Sekine H; Iijima K; Ariizumi K; Yamagishi H; Kitagawa Y; Imatani A; Shimosegawa T
Am J Gastroenterol; 2006 May; 101(5):926-33. PubMed ID: 16573782
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study.
Jing C; Wang J; Zhu M; Bai Z; Zhao B; Zhang J; Yin J; Yang X; Liu Z; Zhang Z; Deng W
Cancer Immunol Immunother; 2022 Nov; 71(11):2597-2608. PubMed ID: 35304622
[TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC
Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859
[TBL] [Abstract][Full Text] [Related]
17. Prognostic nutritional index in predicting survival of patients with gastric or gastroesophageal junction adenocarcinoma: A systematic review.
Fiflis S; Christodoulidis G; Papakonstantinou M; Giakoustidis A; Koukias S; Roussos P; Kouliou MN; Koumarelas KE; Giakoustidis D
World J Gastrointest Oncol; 2024 Feb; 16(2):514-526. PubMed ID: 38425390
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma.
Kato S; Okamura R; Baumgartner JM; Patel H; Leichman L; Kelly K; Sicklick JK; Fanta PT; Lippman SM; Kurzrock R
Clin Cancer Res; 2018 Dec; 24(24):6248-6256. PubMed ID: 30348637
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Nivolumab Plus Chemotherapy vs. Chemotherapy as First-Line Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer/Esophagel Adenocarcinoma in China.
Shu Y; Ding Y; Zhang Q
Front Oncol; 2022; 12():851522. PubMed ID: 35515123
[TBL] [Abstract][Full Text] [Related]
20. Pathologic risk factors of adenocarcinoma of the gastric cardia and gastroesophageal junction.
Carneiro F; Chaves P
Surg Oncol Clin N Am; 2006 Oct; 15(4):697-714. PubMed ID: 17030268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
